FDA Orange Book ยท active-ingredient family
Eltrombopag olamine
Eltrombopag olamine: 2 brands, 10 generics; first approved Nov 20, 2008; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 10 ANDA applications approved.
Earliest patent expiry
Brands (NDA)
2
Generics (ANDA)
10
Listed patents
12
Next patent expiry
Jul 13, 2025
1 yr 2 mo ago
Brand (NDA) products
Originator applications
- PROMACTA KITRLDNOVARTISNDA 20702720182 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 25MG ACID/PACKET FOR SUSPENSION ORAL Rx AB EQ 12.5MG ACID/PACKET FOR SUSPENSION ORAL Rx AB - PROMACTARLDNOVARTISNDA 02229120115 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 25MG ACID TABLET ORAL Rx AB EQ 50MG ACID TABLET ORAL Rx AB EQ 75MG ACID TABLET ORAL Rx AB EQ 12.5MG ACID TABLET ORAL Rx AB EQ 100MG ACID TABLET ORAL Discontinued โ
Generic (ANDA) products (10)
Abbreviated applications
- ELTROMBOPAG OLAMINEACTAVIS LABS FLANDA 2088152026
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 50MG ACID TABLET ORAL Rx AB - ELTROMBOPAG OLAMINEBIOCON PHARMAANDA 22066020264 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12.5MG ACID TABLET ORAL Rx AB EQ 25MG ACID TABLET ORAL Rx AB EQ 50MG ACID TABLET ORAL Rx AB EQ 75MG ACID TABLET ORAL Rx AB - ELTROMBOPAG OLAMINEHIKMAANDA 22003320264 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12.5MG ACID TABLET ORAL Rx AB EQ 25MG ACID TABLET ORAL Rx AB EQ 50MG ACID TABLET ORAL Rx AB EQ 75MG ACID TABLET ORAL Rx AB - ELTROMBOPAG OLAMINEDR REDDYSANDA 21912120264 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12.5MG ACID TABLET ORAL Rx AB EQ 25MG ACID TABLET ORAL Rx AB EQ 50MG ACID TABLET ORAL Rx AB EQ 75MG ACID TABLET ORAL Rx AB - ELTROMBOPAG OLAMINEAMNEALANDA 21288420264 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12.5MG ACID TABLET ORAL Rx AB EQ 50MG ACID TABLET ORAL Rx AB EQ 25MG ACID TABLET ORAL Rx AB EQ 75MG ACID TABLET ORAL Rx AB - ELTROMBOPAG OLAMINEMSNANDA 22025020264 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12.5MG ACID TABLET ORAL Rx AB EQ 25MG ACID TABLET ORAL Rx AB EQ 50MG ACID TABLET ORAL Rx AB EQ 75MG ACID TABLET ORAL Rx AB - ELTROMBOPAG OLAMINESOMERSET THERAPS LLCANDA 21963820264 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12.5MG ACID TABLET ORAL Rx AB EQ 25MG ACID TABLET ORAL Rx AB EQ 50MG ACID TABLET ORAL Rx AB EQ 75MG ACID TABLET ORAL Rx AB - ELTROMBOPAG OLAMINEZYDUS PHARMSANDA 21628120264 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12.5MG ACID TABLET ORAL Rx AB EQ 25MG ACID TABLET ORAL Rx AB EQ 50MG ACID TABLET ORAL Rx AB EQ 75MG ACID TABLET ORAL Rx AB - ELTROMBOPAG OLAMINEHETERO LABS LTD VANDA 20678820254 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12.5MG ACID TABLET ORAL Rx AB EQ 25MG ACID TABLET ORAL Rx AB EQ 50MG ACID TABLET ORAL Rx AB EQ 75MG ACID TABLET ORAL Rx AB - ELTROMBOPAG OLAMINEANNORA PHARMAANDA 21662020242 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 12.5MG ACID/PACKET FOR SUSPENSION ORAL Rx AB EQ 25MG ACID/PACKET FOR SUSPENSION ORAL Rx AB
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 7547719 | 1 yr 2 mo ago | SubstanceProductU-2452 | |
| 7547719*PED | 7 mo ago | ||
| 8052994 | in 11 mo | ProductU-1714 | |
| 8071129 | in 11 mo | ProductU-2451 | |
| 8828430 | in 11 mo | ProductU-1306 | |
| 8062665 | in 11 mo | ProductU-1714 | |
| 8052993 | in 11 mo | ProductU-1714 | |
| 8828430*PED | in 1 yr 6 mo | ||
| 8071129*PED | in 1 yr 6 mo | ||
| 8062665*PED | in 1 yr 6 mo | ||
| 8052993*PED | in 1 yr 6 mo | ||
| 8052994*PED | in 1 yr 6 mo |
Approval history
FDA approval span
First approval
18 yr ago
Most recent approval
2 mo ago
Approvals span 2008โ2026 across 12 FDA applications.
Brand (NDA) 217%
Generic (ANDA) 1083%
Eltrombopag olamine: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.

